AAAAAA
Results:
1-13
|
Results: 13
Authors:
Henze, M
Schuhmacher, J
Hipp, P
Kowalski, J
Becker, DW
Doll, J
Macke, HR
Hofmann, M
Debus, J
Haberkorn, U
Citation: M. Henze et al., PET imaging of somatostatin receptors using [(68)GA]DOTA-D-Phe(1)-Tyr(3)-octreotide: First results in patients with meningiomas, J NUCL MED, 42(7), 2001, pp. 1053-1056
Authors:
Eisenwiener, KP
Powell, P
Macke, HR
Citation: Kp. Eisenwiener et al., A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling, BIOORG MED, 10(18), 2000, pp. 2133-2135
Authors:
Reubi, JC
Schar, JC
Waser, B
Wenger, S
Heppeler, A
Schmitt, JS
Macke, HR
Citation: Jc. Reubi et al., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use, EUR J NUCL, 27(3), 2000, pp. 273-282
Authors:
Froidevaux, S
Heppeler, A
Eberle, AN
Meier, AM
Hausler, M
Beglinger, C
Behe, M
Powell, P
Macke, HR
Citation: S. Froidevaux et al., Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy, ENDOCRINOL, 141(9), 2000, pp. 3304-3312
Authors:
De Jong, M
Breeman, WAP
Bernard, HF
Kooij, PPM
Slooter, GD
Van Eijck, CHJ
Kwekkeboom, DJ
Valkema, R
Macke, HR
Krenning, EP
Citation: M. De Jong et al., Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues, Q J NUCL M, 43(4), 1999, pp. 356-366
Authors:
Paganelli, G
Zoboli, S
Cremonesi, M
Macke, HR
Chinol, M
Citation: G. Paganelli et al., Receptor-mediated radionuclide therapy with Y-90-DOTA-D-Phe(1)-Tyr(3)-octreotide: Preliminary report in cancer patients, CANC BIO R, 14(6), 1999, pp. 477-483
Authors:
Hofland, LJ
Breeman, WAP
Krenning, EP
de Jong, M
Waaijers, M
van Koetsveld, PM
Macke, HR
Lamberts, SWJ
Citation: Lj. Hofland et al., Internalization of [DOTA degrees,I-125-Tyr(3)]octreotide by somatostatin receptor-positive cells in vitro and in vivo: Implications for somatostatin receptor-targeted radioguided surgery, P ASS AM PH, 111(1), 1999, pp. 63-69
Authors:
Merlo, A
Hausmann, O
Wasner, M
Steiner, P
Otte, A
Jermann, E
Freitag, P
Reubi, JC
Muller-Brand, J
Gratzl, O
Macke, HR
Citation: A. Merlo et al., Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue Y-90-labeled DOTA(0)-D-Phe(1)-Tyr(3)-octreotide (DOTATOC): A pilot study in human gliomas, CLIN CANC R, 5(5), 1999, pp. 1025-1033
Authors:
Heppeler, A
Froidevaux, S
Macke, HR
Jermann, E
Behe, M
Powell, P
Hennig, M
Citation: A. Heppeler et al., Radiometal-labelled macrocyclic chelator-derivatised somatostatin analoguewith superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy, CHEM-EUR J, 5(7), 1999, pp. 1974-1981
Authors:
Andre, JP
Toth, E
Fischer, H
Seelig, A
Macke, HR
Merbach, AE
Citation: Jp. Andre et al., High relaxivity for monomeric Gd(DOTA)-based MRI contrast agents, thanks to micellar self-organization, CHEM-EUR J, 5(10), 1999, pp. 2977-2983
Authors:
de Jong, M
Breeman, WAP
Bernard, BF
van Gameren, A
de Bruin, E
Bakker, WH
van der Pluijm, ME
Visser, TJ
Macke, HR
Krenning, EP
Citation: M. De Jong et al., Tumour uptake of the radiolabelled somatostatin analogue [DOTA(0),TYR3]octreotide is dependent on the peptide amount, EUR J NUCL, 26(7), 1999, pp. 693-698
Authors:
Kwekkeboom, DJ
Kooij, PP
Bakker, WH
Macke, HR
Krenning, EP
Citation: Dj. Kwekkeboom et al., Comparison of In-111-DOTA-Tyr(3)-octreotide and In-111-DTPA-octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake, J NUCL MED, 40(5), 1999, pp. 762-767
Authors:
Froidevaux, S
Hintermann, E
Torok, M
Macke, HR
Beglinger, C
Eberle, AN
Citation: S. Froidevaux et al., Differential regulation of somatostatin receptor type 2 (sst 2) expressionin AR4-2J tumor cells implanted into mice during octreotide treatment, CANCER RES, 59(15), 1999, pp. 3652-3657
Risultati:
1-13
|